Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics.
Identifieur interne : 001C69 ( Ncbi/Merge ); précédent : 001C68; suivant : 001C70Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics.
Auteurs : Ernest Milián [Canada] ; Thomas Julien [France] ; Rafael Biaggio [Canada] ; Alina Venereo-Sanchez [Canada] ; Johnny Montes [Canada] ; Aziza P. Manceur [Canada] ; Sven Ansorge [Canada] ; Emma Petiot [France] ; Manuel Rosa-Calatrava [France] ; Amine Kamen [Canada]Source :
- Vaccine [ 1873-2518 ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- croissance et développement : Sous-type H1N1 du virus de la grippe A, Virus recombinants.
- virologie : Cellules HEK293.
- Bioréacteurs, Culture virale, Génétique inverse, Humains, Tests d'inhibition de l'hémagglutination, Transfection, Vaccins antigrippaux.
English descriptors
- KwdEn :
- MESH :
- chemical : Influenza Vaccines.
- growth & development : Influenza A Virus, H1N1 Subtype, Reassortant Viruses.
- virology : HEK293 Cells.
- Bioreactors, Hemagglutination Inhibition Tests, Humans, Reverse Genetics, Transfection, Virus Cultivation.
Abstract
Despite major advances in developing capacities and alternative technologies to egg-based production of influenza vaccines, responsiveness to an influenza pandemic threat is limited by the time it takes to generate a Candidate Vaccine Virus (CVV) as reported by the 2015 WHO Informal Consultation report titled "Influenza Vaccine Response during the Start of a Pandemic". In previous work, we have shown that HEK-293 cell culture in suspension and serum free medium is an efficient production platform for cell culture manufacturing of influenza candidate vaccines. This report, took advantage of, recombinant DNA technology using Reverse Genetics of influenza strains, and advances in the large-scale transfection of suspension cultured HEK-293 cells. We demonstrate the efficient generation of H1N1 with the PR8 backbone reassortant under controlled bioreactor conditions in two sequential steps (transfection/rescue and infection/production). This approach could deliver a CVV for influenza vaccine manufacturing within two-weeks, starting from HA and NA pandemic sequences. Furthermore, the scalability of the transfection technology combined with the HEK-293 platform has been extensively demonstrated at >100L scale for several biologics, including recombinant viruses. Thus, this innovative approach is better suited to rationally engineer and mass produce influenza CVV within significantly shorter timelines to enable an effective global response in pandemic situations.
DOI: 10.1016/j.vaccine.2017.04.065
PubMed: 28495315
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000418
- to stream PubMed, to step Curation: 000418
- to stream PubMed, to step Checkpoint: 000439
Links to Exploration step
pubmed:28495315Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics.</title><author><name sortKey="Milian, Ernest" sort="Milian, Ernest" uniqKey="Milian E" first="Ernest" last="Milián">Ernest Milián</name><affiliation wicri:level="4"><nlm:affiliation>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Julien, Thomas" sort="Julien, Thomas" uniqKey="Julien T" first="Thomas" last="Julien">Thomas Julien</name><affiliation wicri:level="4"><nlm:affiliation>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author><author><name sortKey="Biaggio, Rafael" sort="Biaggio, Rafael" uniqKey="Biaggio R" first="Rafael" last="Biaggio">Rafael Biaggio</name><affiliation wicri:level="4"><nlm:affiliation>Department of Bioengineering, McGill University, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Bioengineering, McGill University, Montréal, Québec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Venereo Sanchez, Alina" sort="Venereo Sanchez, Alina" uniqKey="Venereo Sanchez A" first="Alina" last="Venereo-Sanchez">Alina Venereo-Sanchez</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Montes, Johnny" sort="Montes, Johnny" uniqKey="Montes J" first="Johnny" last="Montes">Johnny Montes</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Manceur, Aziza P" sort="Manceur, Aziza P" uniqKey="Manceur A" first="Aziza P" last="Manceur">Aziza P. Manceur</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Ansorge, Sven" sort="Ansorge, Sven" uniqKey="Ansorge S" first="Sven" last="Ansorge">Sven Ansorge</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Petiot, Emma" sort="Petiot, Emma" uniqKey="Petiot E" first="Emma" last="Petiot">Emma Petiot</name><affiliation wicri:level="4"><nlm:affiliation>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author><author><name sortKey="Rosa Calatrava, Manuel" sort="Rosa Calatrava, Manuel" uniqKey="Rosa Calatrava M" first="Manuel" last="Rosa-Calatrava">Manuel Rosa-Calatrava</name><affiliation wicri:level="4"><nlm:affiliation>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author><author><name sortKey="Kamen, Amine" sort="Kamen, Amine" uniqKey="Kamen A" first="Amine" last="Kamen">Amine Kamen</name><affiliation wicri:level="4"><nlm:affiliation>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada. Electronic address: amine.kamen@mcgill.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28495315</idno><idno type="pmid">28495315</idno><idno type="doi">10.1016/j.vaccine.2017.04.065</idno><idno type="wicri:Area/PubMed/Corpus">000418</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000418</idno><idno type="wicri:Area/PubMed/Curation">000418</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000418</idno><idno type="wicri:Area/PubMed/Checkpoint">000439</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000439</idno><idno type="wicri:Area/Ncbi/Merge">001C69</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics.</title><author><name sortKey="Milian, Ernest" sort="Milian, Ernest" uniqKey="Milian E" first="Ernest" last="Milián">Ernest Milián</name><affiliation wicri:level="4"><nlm:affiliation>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Julien, Thomas" sort="Julien, Thomas" uniqKey="Julien T" first="Thomas" last="Julien">Thomas Julien</name><affiliation wicri:level="4"><nlm:affiliation>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author><author><name sortKey="Biaggio, Rafael" sort="Biaggio, Rafael" uniqKey="Biaggio R" first="Rafael" last="Biaggio">Rafael Biaggio</name><affiliation wicri:level="4"><nlm:affiliation>Department of Bioengineering, McGill University, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Bioengineering, McGill University, Montréal, Québec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Venereo Sanchez, Alina" sort="Venereo Sanchez, Alina" uniqKey="Venereo Sanchez A" first="Alina" last="Venereo-Sanchez">Alina Venereo-Sanchez</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Montes, Johnny" sort="Montes, Johnny" uniqKey="Montes J" first="Johnny" last="Montes">Johnny Montes</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Manceur, Aziza P" sort="Manceur, Aziza P" uniqKey="Manceur A" first="Aziza P" last="Manceur">Aziza P. Manceur</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Ansorge, Sven" sort="Ansorge, Sven" uniqKey="Ansorge S" first="Sven" last="Ansorge">Sven Ansorge</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Petiot, Emma" sort="Petiot, Emma" uniqKey="Petiot E" first="Emma" last="Petiot">Emma Petiot</name><affiliation wicri:level="4"><nlm:affiliation>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author><author><name sortKey="Rosa Calatrava, Manuel" sort="Rosa Calatrava, Manuel" uniqKey="Rosa Calatrava M" first="Manuel" last="Rosa-Calatrava">Manuel Rosa-Calatrava</name><affiliation wicri:level="4"><nlm:affiliation>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author><author><name sortKey="Kamen, Amine" sort="Kamen, Amine" uniqKey="Kamen A" first="Amine" last="Kamen">Amine Kamen</name><affiliation wicri:level="4"><nlm:affiliation>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada. Electronic address: amine.kamen@mcgill.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bioreactors</term><term>HEK293 Cells (virology)</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (growth & development)</term><term>Influenza Vaccines</term><term>Reassortant Viruses (growth & development)</term><term>Reverse Genetics</term><term>Transfection</term><term>Virus Cultivation</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Bioréacteurs</term><term>Cellules HEK293 (virologie)</term><term>Culture virale</term><term>Génétique inverse</term><term>Humains</term><term>Sous-type H1N1 du virus de la grippe A (croissance et développement)</term><term>Tests d'inhibition de l'hémagglutination</term><term>Transfection</term><term>Vaccins antigrippaux</term><term>Virus recombinants (croissance et développement)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Virus recombinants</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Reassortant Viruses</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules HEK293</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HEK293 Cells</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Bioreactors</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Reverse Genetics</term><term>Transfection</term><term>Virus Cultivation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Bioréacteurs</term><term>Culture virale</term><term>Génétique inverse</term><term>Humains</term><term>Tests d'inhibition de l'hémagglutination</term><term>Transfection</term><term>Vaccins antigrippaux</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Despite major advances in developing capacities and alternative technologies to egg-based production of influenza vaccines, responsiveness to an influenza pandemic threat is limited by the time it takes to generate a Candidate Vaccine Virus (CVV) as reported by the 2015 WHO Informal Consultation report titled "Influenza Vaccine Response during the Start of a Pandemic". In previous work, we have shown that HEK-293 cell culture in suspension and serum free medium is an efficient production platform for cell culture manufacturing of influenza candidate vaccines. This report, took advantage of, recombinant DNA technology using Reverse Genetics of influenza strains, and advances in the large-scale transfection of suspension cultured HEK-293 cells. We demonstrate the efficient generation of H1N1 with the PR8 backbone reassortant under controlled bioreactor conditions in two sequential steps (transfection/rescue and infection/production). This approach could deliver a CVV for influenza vaccine manufacturing within two-weeks, starting from HA and NA pandemic sequences. Furthermore, the scalability of the transfection technology combined with the HEK-293 platform has been extensively demonstrated at >100L scale for several biologics, including recombinant viruses. Thus, this innovative approach is better suited to rationally engineer and mass produce influenza CVV within significantly shorter timelines to enable an effective global response in pandemic situations.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28495315</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>26</Issue><PubDate><Year>2017</Year><Month>06</Month><Day>08</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics.</ArticleTitle><Pagination><MedlinePgn>3423-3430</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(17)30557-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2017.04.065</ELocationID><Abstract><AbstractText>Despite major advances in developing capacities and alternative technologies to egg-based production of influenza vaccines, responsiveness to an influenza pandemic threat is limited by the time it takes to generate a Candidate Vaccine Virus (CVV) as reported by the 2015 WHO Informal Consultation report titled "Influenza Vaccine Response during the Start of a Pandemic". In previous work, we have shown that HEK-293 cell culture in suspension and serum free medium is an efficient production platform for cell culture manufacturing of influenza candidate vaccines. This report, took advantage of, recombinant DNA technology using Reverse Genetics of influenza strains, and advances in the large-scale transfection of suspension cultured HEK-293 cells. We demonstrate the efficient generation of H1N1 with the PR8 backbone reassortant under controlled bioreactor conditions in two sequential steps (transfection/rescue and infection/production). This approach could deliver a CVV for influenza vaccine manufacturing within two-weeks, starting from HA and NA pandemic sequences. Furthermore, the scalability of the transfection technology combined with the HEK-293 platform has been extensively demonstrated at >100L scale for several biologics, including recombinant viruses. Thus, this innovative approach is better suited to rationally engineer and mass produce influenza CVV within significantly shorter timelines to enable an effective global response in pandemic situations.</AbstractText><CopyrightInformation>Crown Copyright © 2017. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milián</LastName><ForeName>Ernest</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biaggio</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, McGill University, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venereo-Sanchez</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montes</LastName><ForeName>Johnny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manceur</LastName><ForeName>Aziza P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansorge</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petiot</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa-Calatrava</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Virologie et Pathologie Humaine - VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamen</LastName><ForeName>Amine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, McGill University, Montréal, Québec, Canada; Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada. Electronic address: amine.kamen@mcgill.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019149" MajorTopicYN="N">Bioreactors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="Y">growth & development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059386" MajorTopicYN="Y">Reverse Genetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014776" MajorTopicYN="Y">Virus Cultivation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Candidate Vaccine Virus (CVV)</Keyword><Keyword MajorTopicYN="Y">Influenza virus</Keyword><Keyword MajorTopicYN="Y">Large-scale</Keyword><Keyword MajorTopicYN="Y">Pandemic</Keyword><Keyword MajorTopicYN="Y">Reverse genetics</Keyword><Keyword MajorTopicYN="Y">Suspension cell culture</Keyword><Keyword MajorTopicYN="Y">Transient transfection</Keyword><Keyword MajorTopicYN="Y">Vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>01</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>04</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28495315</ArticleId><ArticleId IdType="pii">S0264-410X(17)30557-1</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2017.04.065</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Québec</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li><li>Montréal</li></settlement><orgName><li>Université Claude Bernard Lyon 1</li><li>Université McGill</li></orgName></list><tree><country name="Canada"><region name="Québec"><name sortKey="Milian, Ernest" sort="Milian, Ernest" uniqKey="Milian E" first="Ernest" last="Milián">Ernest Milián</name></region><name sortKey="Ansorge, Sven" sort="Ansorge, Sven" uniqKey="Ansorge S" first="Sven" last="Ansorge">Sven Ansorge</name><name sortKey="Biaggio, Rafael" sort="Biaggio, Rafael" uniqKey="Biaggio R" first="Rafael" last="Biaggio">Rafael Biaggio</name><name sortKey="Kamen, Amine" sort="Kamen, Amine" uniqKey="Kamen A" first="Amine" last="Kamen">Amine Kamen</name><name sortKey="Manceur, Aziza P" sort="Manceur, Aziza P" uniqKey="Manceur A" first="Aziza P" last="Manceur">Aziza P. Manceur</name><name sortKey="Montes, Johnny" sort="Montes, Johnny" uniqKey="Montes J" first="Johnny" last="Montes">Johnny Montes</name><name sortKey="Venereo Sanchez, Alina" sort="Venereo Sanchez, Alina" uniqKey="Venereo Sanchez A" first="Alina" last="Venereo-Sanchez">Alina Venereo-Sanchez</name></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Julien, Thomas" sort="Julien, Thomas" uniqKey="Julien T" first="Thomas" last="Julien">Thomas Julien</name></region><name sortKey="Petiot, Emma" sort="Petiot, Emma" uniqKey="Petiot E" first="Emma" last="Petiot">Emma Petiot</name><name sortKey="Rosa Calatrava, Manuel" sort="Rosa Calatrava, Manuel" uniqKey="Rosa Calatrava M" first="Manuel" last="Rosa-Calatrava">Manuel Rosa-Calatrava</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C69 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001C69 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28495315
|texte= Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28495315" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |